NASDAQ:LEXX Lexaria Bioscience (LEXX) Stock Price, News & Analysis $0.58 +0.02 (+3.07%) Closing price 04:00 PM EasternExtended Trading$0.60 +0.02 (+4.11%) As of 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Lexaria Bioscience Stock (NASDAQ:LEXX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Lexaria Bioscience alerts:Sign Up Key Stats Today's Range$0.55▼$0.5950-Day Range$0.56▼$1.0652-Week Range$0.46▼$1.55Volume70,471 shsAverage Volume189,320 shsMarket Capitalization$14.31 millionP/E RatioN/ADividend YieldN/APrice Target$1.50Consensus RatingHold Company Overview Lexaria Bioscience Corp. (NASDAQ: LEXX) is a biotech company specializing in the development and commercialization of proprietary drug delivery platforms. The company’s flagship technology, DehydraTECH, is designed to improve the oral bioavailability, onset time and overall efficiency of active molecules such as cannabinoids, nicotine and other lipophilic compounds. Lexaria’s platform seeks to address absorption challenges commonly associated with oral delivery by enhancing the rate and extent at which compounds enter the bloodstream. Founded in 2014 and headquartered in Kelowna, British Columbia, Lexaria operates in the pharmaceutical, nutraceutical and consumer product markets. The company pursues partnerships and licensing agreements with industry participants to incorporate its delivery technology into a range of finished goods, including functional foods, beverages and over-the-counter formulations. In addition to cannabinoids, Lexaria has extended its research to nicotine and vitamin molecules, reflecting a strategy to serve multiple end-use sectors. Lexaria’s research efforts include preclinical and clinical investigations to validate the efficacy and safety of its technology. The company has collaborated with academic and contract research organizations in North America to conduct pharmacokinetic and toxicology studies. These studies support regulatory filings and form the foundation for future pharmaceutical and nutraceutical product launches. Leadership at Lexaria is led by President and Chief Executive Officer Christopher Bunka, who oversees the company’s strategic direction, partnerships and product development initiatives. Backed by a team with expertise in pharmaceutical sciences, regulatory affairs and commercial operations, Lexaria Bioscience continues to advance its mission of delivering next-generation oral absorption technologies to the global health, wellness and therapeutic markets.AI Generated. May Contain Errors. Read More Lexaria Bioscience Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks45th Percentile Overall ScoreLEXX MarketRank™: Lexaria Bioscience scored higher than 45% of companies evaluated by MarketBeat, and ranked 589th out of 851 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingLexaria Bioscience has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialLexaria Bioscience has a consensus price target of $1.50, representing about 159.8% upside from its current price of $0.58.Amount of Analyst CoverageLexaria Bioscience has only been the subject of 1 research reports in the past 90 days.Read more about Lexaria Bioscience's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Lexaria Bioscience are expected to grow in the coming year, from ($0.36) to ($0.31) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lexaria Bioscience is -1.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lexaria Bioscience is -1.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLexaria Bioscience has a P/B Ratio of 4.44. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Lexaria Bioscience's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.52% of the float of Lexaria Bioscience has been sold short.Short Interest Ratio / Days to CoverLexaria Bioscience has a short interest ratio ("days to cover") of 1.44, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lexaria Bioscience has recently decreased by 9.59%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLexaria Bioscience does not currently pay a dividend.Dividend GrowthLexaria Bioscience does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A MarketBeat Follows2 people have added Lexaria Bioscience to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Lexaria Bioscience insiders have not sold or bought any company stock.Percentage Held by Insiders8.39% of the stock of Lexaria Bioscience is held by insiders.Percentage Held by Institutions13.06% of the stock of Lexaria Bioscience is held by institutions.Read more about Lexaria Bioscience's insider trading history. Receive LEXX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lexaria Bioscience and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LEXX Stock News HeadlinesInventiva (NASDAQ:IVA) vs. Lexaria Bioscience (NASDAQ:LEXX) Critical ComparisonMay 11, 2026 | americanbankingnews.comLexaria Bioscience Corp.: Lexaria Bioscience Releases Second Episode of Investor Video SeriesMay 7, 2026 | finanznachrichten.de$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s known for playing his cards “close to the vest”… Is going to give you the name and ticker symbol of a company he believes will skyrocket thanks to the coming Starlink IPO…May 19 at 1:00 AM | Paradigm Press (Ad)Lexaria Bioscience Corp.April 15, 2026 | edition.cnn.comLexaria Bioscience (NASDAQ:LEXX) Will Have To Spend Its Cash WiselyApril 15, 2026 | finance.yahoo.comLexaria Bioscience Corp.: Lexaria Applauds Eli Lilly's Foundayo Drug ApprovalApril 7, 2026 | finanznachrichten.deLexaria Bioscience Corp.: Lexaria's Robust Patent Portfolio Continues to GrowMarch 26, 2026 | finanznachrichten.deLexaria Launches 2026 R&D Push to Advance GLP-1 and Cannabidiol Drug DeliveryMarch 15, 2026 | theglobeandmail.comSee More Headlines LEXX Stock Analysis - Frequently Asked Questions How have LEXX shares performed this year? Lexaria Bioscience's stock was trading at $0.6170 on January 1st, 2026. Since then, LEXX stock has decreased by 6.4% and is now trading at $0.5773. How were Lexaria Bioscience's earnings last quarter? Lexaria Bioscience Corp. (NASDAQ:LEXX) issued its earnings results on Monday, April, 13th. The company reported ($0.06) EPS for the quarter, topping analysts' consensus estimates of ($0.10) by $0.04. The business earned $0.02 million during the quarter, compared to analysts' expectations of $0.05 million. Lexaria Bioscience had a negative net margin of 1,685.84% and a negative trailing twelve-month return on equity of 206.02%. How do I buy shares of Lexaria Bioscience? Shares of LEXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Lexaria Bioscience own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lexaria Bioscience investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), Arista Networks (ANET) and Builders FirstSource (BLDR). Company Calendar Last Earnings4/13/2026Today5/19/2026Next Earnings (Estimated)7/13/2026Fiscal Year End8/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (3w+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 For the last 3 weeks, LEXX's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:LEXX CIK1348362 Webwww.lexariabioscience.com Phone(250) 765-6424FaxN/AEmployees7Year FoundedN/APrice Target and Rating Average Price Target for Lexaria Bioscience$1.50 High Price Target$1.50 Low Price Target$1.50 Potential Upside/Downside+159.8%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($0.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$11.90 million Net Margins-1,685.84% Pretax Margin-2,590.49% Return on Equity-206.02% Return on Assets-162.53% Debt Debt-to-Equity RatioN/A Current Ratio26.84 Quick Ratio26.84 Sales & Book Value Annual Sales$710 thousand Price / Sales20.16 Cash FlowN/A Price / Cash FlowN/A Book Value$0.13 per share Price / Book4.44Miscellaneous Outstanding Shares24,790,000Free Float22,707,000Market Cap$14.31 million OptionableNot Optionable Beta0.37 Social Links The 10 Best AI Stocks to Own in 2026Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:LEXX) was last updated on 5/19/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexaria Bioscience Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexaria Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
